Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation

Ähnliche Einträge

• Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
  von: Francesca Perutelli, et al.
  Veröffentlicht: (2025)
• Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia
  von: Francesca A. M. Kinsella, et al.
  Veröffentlicht: (2024)
• A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy
  von: Xing‐yu Cao, et al.
  Veröffentlicht: (2024)
• Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation
  von: Tingting Zhang, et al.
  Veröffentlicht: (2024)
• Long‐term remission of TP53‐mutated therapy‐related acute myeloid leukaemia following allogeneic stem cell transplantation in a heart transplant recipient: A case report and literature review
  von: Annie Xiao, et al.
  Veröffentlicht: (2024)